Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:CRSP NASDAQ:NTLA NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$28.20+1.9%$22.24$13.52▼$35.25$2.80B2.252.58 million shs1.44 million shsCRSPCRISPR Therapeutics$67.21+1.0%$61.46$30.04▼$78.48$6.05B1.842.76 million shs1.55 million shsNTLAIntellia Therapeutics$25.89+5.3%$16.53$5.90▼$28.25$2.64B2.376.62 million shs2.76 million shsVRTXVertex Pharmaceuticals$422.63-0.9%$398.38$362.50▼$519.88$109.34B0.431.50 million shs1.76 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+1.88%+9.34%+18.84%+29.83%+29.24%CRSPCRISPR Therapeutics+1.04%-1.78%+10.62%+3.78%+46.11%NTLAIntellia Therapeutics+5.33%+3.93%+51.58%+90.37%+29.84%VRTXVertex Pharmaceuticals-0.89%+3.43%+11.30%-10.01%-10.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$28.20+1.9%$22.24$13.52▼$35.25$2.80B2.252.58 million shs1.44 million shsCRSPCRISPR Therapeutics$67.21+1.0%$61.46$30.04▼$78.48$6.05B1.842.76 million shs1.55 million shsNTLAIntellia Therapeutics$25.89+5.3%$16.53$5.90▼$28.25$2.64B2.376.62 million shs2.76 million shsVRTXVertex Pharmaceuticals$422.63-0.9%$398.38$362.50▼$519.88$109.34B0.431.50 million shs1.76 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+1.88%+9.34%+18.84%+29.83%+29.24%CRSPCRISPR Therapeutics+1.04%-1.78%+10.62%+3.78%+46.11%NTLAIntellia Therapeutics+5.33%+3.93%+51.58%+90.37%+29.84%VRTXVertex Pharmaceuticals-0.89%+3.43%+11.30%-10.01%-10.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 2.94Moderate Buy$45.9262.83% UpsideCRSPCRISPR Therapeutics 2.42Hold$72.598.00% UpsideNTLAIntellia Therapeutics 2.52Moderate Buy$27.957.96% UpsideVRTXVertex Pharmaceuticals 2.62Moderate Buy$494.3816.98% UpsideCurrent Analyst Ratings BreakdownLatest CRSP, VRTX, NTLA, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025CRSPCRISPR TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $93.0010/13/2025CRSPCRISPR TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$75.0010/10/2025VRTXVertex PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$439.00 ➝ $438.0010/10/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/10/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$81.0010/9/2025BEAMBeam TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$48.00 ➝ $46.0010/9/2025BEAMBeam TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold ➝ Buy$41.0010/8/2025BEAMBeam TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CRSPCRISPR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NTLAIntellia TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VRTXVertex PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$517.00 ➝ $530.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M44.91N/AN/A$8.86 per share3.18CRSPCRISPR Therapeutics$37.31M163.84N/AN/A$22.64 per share2.97NTLAIntellia Therapeutics$57.88M48.02N/AN/A$8.56 per share3.02VRTXVertex Pharmaceuticals$11.02B9.83N/AN/A$63.72 per share6.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$4.69N/AN/AN/A-908.48%-57.48%-45.04%11/6/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M$13.9930.2124.14N/A31.86%23.91%17.14%11/3/2025 (Estimated)Latest CRSP, VRTX, NTLA, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025NTLAIntellia Therapeutics-$1.00N/AN/AN/AN/AN/A11/4/2025Q3 2025BEAMBeam Therapeutics-$1.03N/AN/AN/A$12.83 millionN/A11/4/2025Q3 2025CRSPCRISPR Therapeutics-$1.32N/AN/AN/A$8.74 millionN/A11/3/2025Q3 2025VRTXVertex Pharmaceuticals$4.56N/AN/AN/A$3.05 billionN/A8/7/2025Q2 2025NTLAIntellia Therapeutics-$1.03-$0.99+$0.04-$0.98$12.26 million$14.25 million8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 million8/4/2025Q2 2025VRTXVertex Pharmaceuticals$4.24$4.52+$0.28$3.99$2.90 billion$2.94 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A6.756.75CRSPCRISPR TherapeuticsN/A16.6116.61NTLAIntellia TherapeuticsN/A5.195.19VRTXVertex PharmaceuticalsN/A2.522.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%CRSPCRISPR Therapeutics69.20%NTLAIntellia Therapeutics88.77%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.50%CRSPCRISPR Therapeutics4.30%NTLAIntellia Therapeutics3.10%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510101.16 million97.62 millionOptionableCRSPCRISPR Therapeutics46090.95 million87.04 millionOptionableNTLAIntellia Therapeutics600107.35 million104.02 millionOptionableVRTXVertex Pharmaceuticals6,100256.39 million255.88 millionOptionableCRSP, VRTX, NTLA, and BEAM HeadlinesRecent News About These CompaniesVertex Pharmaceuticals Incorporated: Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK at the North American Cystic Fibrosis ConferenceOctober 23 at 12:07 PM | finanznachrichten.deBank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX)October 22 at 12:30 AM | insidermonkey.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItOctober 22 at 10:00 AM | zacks.comARK Investment Management LLC Sells 2,281 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 22 at 9:13 AM | marketbeat.com2,440 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Phoenix Financial Ltd.October 22 at 6:01 AM | marketbeat.comVertex Pharmaceuticals price target lowered to $563 from $565 at BofAOctober 21 at 2:59 PM | msn.comHealthcare's Shift to Prevention Gains Momentum as Markets Reach Critical MassOctober 21 at 9:58 AM | baystreet.caVertex Pharmaceuticals’ Promising Kidney Franchise: Andrew Fein’s Buy Rating on Innovative Povetacicept and Strategic ExpansionOctober 21 at 8:10 AM | tipranks.comVertex Pharmaceuticals: Strong Market Position and Growth Potential Reinforce Buy RatingOctober 21 at 6:51 AM | tipranks.comDekaBank Deutsche Girozentrale Boosts Stock Position in Vertex Pharmaceuticals Incorporated $VRTXOctober 21 at 5:28 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Sold by William Blair Investment Management LLCOctober 21 at 4:27 AM | marketbeat.comStratos Wealth Partners LTD. Sells 1,083 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 21 at 4:17 AM | marketbeat.comBogart Wealth LLC Purchases 6,240 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 20, 2025 | marketbeat.comNordea Investment Management AB Has $10.89 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTXOctober 20, 2025 | marketbeat.comMutual of America Capital Management LLC Sells 2,069 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 19, 2025 | marketbeat.comCwm LLC Sells 776 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 18, 2025 | marketbeat.comVertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney WeekOctober 17, 2025 | businesswire.comChevy Chase Trust Holdings LLC Sells 2,121 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 17, 2025 | marketbeat.comTweedy Browne Co LLC Sells 1,063 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 17, 2025 | marketbeat.comMattson Financial Services LLC Invests $1.74 Million in Vertex Pharmaceuticals Incorporated $VRTXOctober 17, 2025 | marketbeat.comTurtle Creek Wealth Advisors LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTXOctober 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRSP, VRTX, NTLA, and BEAM Company DescriptionsBeam Therapeutics NASDAQ:BEAM$28.20 +0.52 (+1.88%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$28.54 +0.35 (+1.22%) As of 10/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.CRISPR Therapeutics NASDAQ:CRSP$67.21 +0.69 (+1.04%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$67.22 +0.02 (+0.02%) As of 10/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Intellia Therapeutics NASDAQ:NTLA$25.89 +1.31 (+5.33%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$25.92 +0.03 (+0.12%) As of 10/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Vertex Pharmaceuticals NASDAQ:VRTX$422.63 -3.81 (-0.89%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$419.94 -2.69 (-0.64%) As of 10/23/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
